Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Registration Number
- NCT05502237
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1069
-
Life expectancy ≥ 3 months.
-
Pathologically documented NSCLC that meets both of the criteria below:
- Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on American Joint Committee on Cancer (AJCC), Eighth Edition).
- Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations.
-
Have no actionable genomic alterations such as ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other driver oncogenes with approved frontline therapies.
-
Have not received prior systemic treatment for metastatic NSCLC.
-
Measurable disease per RECIST v1.1 criteria by investigator assessment.
-
Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
-
Have adequate organ functions.
Key
- Have mixed small-cell lung cancer (SCLC) and NSCLC histology.
- Positive serum pregnancy test or individuals who are breastfeeding or have plans to breastfeed during the study period.
- Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint.
- Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
- Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment.
- Have an active autoimmune disease that required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
- Are receiving chronic systemic steroids.
- Have significant third-space fluid retention.
- Have untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrollment.
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- Has had an allogenic tissue/solid organ transplant.
- Have received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
- Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Zimberelimab (ZIM) + Chemotherapy Nab-paclitaxel Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Nab-paclitaxel Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Pembrolizumab (PEMBRO) + Chemotherapy Nab-paclitaxel Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Domvanalimab Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Zimberelimab Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Carboplatin Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Cisplatin Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Pemetrexed Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) +Domvanalimab (DOM) + Chemotherapy Paclitaxel Participants will receive ZIM 360 mg + DOM 1200 mg (up to 35 doses) with chemotherapy every 3 weeks (Q3W) on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin area under the concentration versus time curve (AUC)5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Pembrolizumab (PEMBRO) + Chemotherapy Paclitaxel Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Pembrolizumab (PEMBRO) + Chemotherapy Pembrolizumab Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Pembrolizumab (PEMBRO) + Chemotherapy Carboplatin Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Pembrolizumab (PEMBRO) + Chemotherapy Cisplatin Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Pembrolizumab (PEMBRO) + Chemotherapy Pemetrexed Participants will receive PEMBRO 200 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles. After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) + Chemotherapy Zimberelimab Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) + Chemotherapy Carboplatin Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) + Chemotherapy Cisplatin Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) + Chemotherapy Paclitaxel Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles. Zimberelimab (ZIM) + Chemotherapy Pemetrexed Participants will receive ZIM 360 mg (up to 35 doses) with chemotherapy Q3W on Day 1 of each 21-day cycle. Choice of chemotherapy is dependent on histology. * Participants with nonsquamous histology will receive cisplatin 75 mg/m\^2 or carboplatin AUC 5 + pemetrexed 500 mg/m\^2 Q3W for first 4 cycles After the completion of the first 4 cycles, participants with nonsquamous histology may continue with maintenance pemetrexed 500 mg/m\^2 Q3W until disease progression or intolerable toxicities. * Participants with squamous histology will receive carboplatin AUC 6 Q3W with paclitaxel 200 mg/m\^2 Q3W or nab-paclitaxel 100 mg/m\^2 weekly (QW) for first 4 cycles.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) in Participants With Positive Programmed Cell Death-Ligand 1 (PD-L1) Expression (≥1%Tumor Cells) and in all Randomized Participants. Up to 68 months OS is defined as the time from the date of randomization to the date of death from any cause.
- Secondary Outcome Measures
Name Time Method Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Upt to 50 months PFS is defined as the time from the date of randomization until disease progression (PD) or death from any cause, whichever comes first.
Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1 Up to 50 Months ORR is defined as the proportion of participants who have achieved a complete response (CR) or partial response (PR) that is confirmed at least 4 weeks later.
Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1 Up to 50 Months DOR is defined as the time from the first response (CR or PR), to the first documented PD or death from any cause, whichever comes first.
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) First dose date up to 50 months plus 30 days Percentage of Participants Experiencing Clinical Laboratory Abnormalities First dose date up to 50 months plus 30 days Time to First Symptom Deterioration in Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Total Score Baseline, Up to 50 Months The NSCLC-SAQ is a patient reported outcome measure with seven items assessing five symptom concepts of NSCLC: cough, pain, dyspnea, fatigue, and appetite. Each item is rated using a five-point verbal rating scale from "No \<symptom\> At All" to "Very severe \<symptom\>" or from "Never to Always," corresponding to a score of 0 to 4. The sum of all 5 domain scores will be computed, if any scores are missing, a total score will not be computed. The total score ranges between 0 and 20 with higher scores indicating more severe symptoms.
Trial Locations
- Locations (224)
West China Hospital Sichuan University
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Deyang People's Hospital
🇨🇳Deyang, China
Palo Verde Hematology Oncology Ltd
🇺🇸Glendale, Arizona, United States
California Cancer Associates for Research and Excellence
🇺🇸San Marcos, California, United States
Texas Oncology
🇺🇸Dallas, Texas, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
Eastern CT Hematology and Oncology Associates
🇺🇸Norwich, Connecticut, United States
Lake City Cancer Care
🇺🇸Lake City, Florida, United States
Florida Cancer Specialists
🇺🇸Sarasota, Florida, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Peachtree Hematology Oncology Consultants
🇺🇸Atlanta, Georgia, United States
Illinois Cancer Care
🇺🇸Peoria, Illinois, United States
Messino Cancer Centers
🇺🇸Asheville, North Carolina, United States
Oncology Hematology Care, Inc.
🇺🇸Cincinnati, Ohio, United States
Hematology & Oncology Associates
🇺🇸Eugene, Oregon, United States
AHN Allegheny General Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Arlington Cancer Center
🇺🇸Arlington, Texas, United States
Texas Oncology - Austin
🇺🇸Austin, Texas, United States
Texas Oncology- Denison
🇺🇸Sherman, Texas, United States
US Oncology Investigational Products Center (IPC)
🇺🇸Arlington, Virginia, United States
Ziekenhuis Gelderse Vallei
🇳🇱Ede, Netherlands
Oncology and Hematology Associates of Southwest Virginia, Inc
🇺🇸Blacksburg, Virginia, United States
Northwest Cancer Specialists, PC
🇺🇸Vancouver, Washington, United States
Investigaciones CORI S.R.L.
🇦🇷Capital, Argentina
Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica
🇦🇷Cardoba, Argentina
Centro Medico Barrio Parque
🇦🇷Ciudad Autanoma Buenos Aires, Argentina
Sanatorio Allende
🇦🇷Cordoba, Argentina
Sanatorio Britanico de Rosario
🇦🇷Rosario, Argentina
Sanatorio Parque de Rosario
🇦🇷Rosario, Argentina
Hospital Provincial del Centenario
🇦🇷Rosario, Argentina
Instituto Medico de la Fundacion Estudios Clinicos
🇦🇷Rosario, Argentina
CAIPO - Centro para la Atención Integral del Paciente Oncológico
🇦🇷San Miguel de Tucumán, Argentina
Clínica Viedma
🇦🇷Viedma, Argentina
Klinikum Klagenfurt am Woerthersee
🇦🇹Klagenfurt Am Woerthersee, Austria
Ordensklinikum Linz GmbH, Elisabethinen
🇦🇹Linz, Austria
Klinikum Wels-Grieskirchen
🇦🇹Wels, Austria
Krankenhaus Nord - Klinik Floridsdorf
🇦🇹Wien, Austria
Algemeen Ziekenhuis Sint-Lucas
🇧🇪Aalst, Belgium
Grand Hopital de Charleroi asbl (GHdC)
🇧🇪Charleroi, Belgium
AZ Sint-Maarten
🇧🇪Mechelen, Belgium
CHU UCL Namur / Site Sainte Elisabeth
🇧🇪Namur, Belgium
Cenantron Centro Avançado de Tratamento Oncologico Ltda
🇧🇷Belo Horizonte, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
🇧🇷Cachoeiro De Itapemirim, Brazil
Fundacao Universidade De Caxias Do Sul - FUCS/RS
🇧🇷Caxias Do Sul, Brazil
Instituto do Câncer do Ceará - ICC
🇧🇷Fortaleza, Brazil
Oncosite - Centro de Pesquisa Clinica em Oncologia LTDA
🇧🇷Ijui, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital de Clínicas de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Hospital Ana Nery Santa Cruz do Sul
🇧🇷Santa Cruz Do Sul, Brazil
Centro Des Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho
🇧🇷Sao Paolo, Brazil
Instituto Brasiliero de Controle do Cancer IBCC
🇧🇷Sao Paulo, Brazil
Centre Integre de sante et de services sociaux de la Monteregie Centre
🇨🇦Greenfield Park, Canada
Moncton Hospital
🇨🇦Moncton, Canada
CISSS des Laurentides
🇨🇦Quebec, Canada
Centre de santé et services sociaux de Rimouski-Neigette
🇨🇦Rimouski, Canada
BC Cancer - Victoria
🇨🇦Victoria, Canada
Clinica Alemana de Santiago
🇨🇱Las Condes, Chile
Orlandioncologia
🇨🇱Providencia, Chile
Oncovida- Santiago
🇨🇱Providencia, Chile
Clinica Puerto Montt
🇨🇱Puerto Montt, Chile
Biocinetic
🇨🇱Santiago, Chile
James Lind Centro de Investigacion del Cancer
🇨🇱Temuco, Chile
Oncocentro APYS
🇨🇱Vina del Mar, Chile
Fujian Cancer Hospital
🇨🇳Fuzhou, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, China
Guangzhou First People's Hospital
🇨🇳Guangzhou, China
Nanfang Hospital, Southern Medical University
🇨🇳Guangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, China
Anhui Chest Hospital
🇨🇳Hefei, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Jiangxi, China
Shandong Cancer Hospital
🇨🇳Jinan, China
Jiangxi Chest Hospital
🇨🇳Nanchang, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
Guangxi Medical University Cancer Hospital
🇨🇳Nanning, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Shanghai Pulmonary Hospital
🇨🇳Shanghai, China
Cancer Hospital of Shantou University Medical College
🇨🇳Shantou, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, China
Tongji Hospital Tongji Medical College of Hust
🇨🇳Wuhan, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳Xi'an, China
The First Affiliated Hospital of Xinxiang Medical College
🇨🇳Xinxiang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Ambroise-Pare Hospital, Assistance Publique - Hopitaux de Paris
🇫🇷Boulogne-Billancourt, France
CHU de Caen
🇫🇷Caen, France
Clinique Victor Hugo, Centre de Cancerologie de la Sarthe
🇫🇷Le Mans, France
Hopital Nord
🇫🇷Marseille, France
Institut de Cancer de Montpellier (ICM) - Val d'Aurelle
🇫🇷Montpellier, France
Centre Antoine Lacassagne
🇫🇷Nice, France
Institut de cancerologie de l'ouest (ICO)
🇫🇷Saint-Herblain, France
Hopital d'Instruction des Armees (HIA) Begin
🇫🇷Saint-Mandé, France
Centre Hospitalier de Saint-Quentin
🇫🇷Saint-Quentin, France
Institut de Cancerologie Strasbourg Europe (ICANS)
🇫🇷Strasbourg, France
Hôpital Foch
🇫🇷Suresnes, France
CHI de Toulon la Seyne-sur-Mer Hopital Sainte Musse
🇫🇷Toulon cedex, France
Augusta-Kranken-Anstalt gGmbh Klinik für Hämatologie Onkologie und Palliativmedizin
🇩🇪Bochum, Germany
Klinikum Chemnitz gGmbH
🇩🇪Chemnitz, Germany
Universitatsklinikum Essen / Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung)
🇩🇪Essen, Germany
Universitätsklinikum Freiburg, Klinik für Innere Medizin I Hämatologie, Onkologie und Stammzelltransplantation
🇩🇪Freiburg, Germany
LungenClinic Grosshansdorf
🇩🇪Grosshansdorf, Germany
Krankenhaus Martha-Maria Halle Dölau
🇩🇪Halle, Germany
Asklepios Kliniken Hamburg
🇩🇪Hamburg, Germany
Katholisches Marienkrankenhaus gGmbH
🇩🇪Hamburg, Germany
Lungenklinik Hemer, Zentrum fur Pneumologie and Thoraxchirurgie
🇩🇪Hemer, Germany
Vincentius-Diakonissen-Kliniken gAG, St. Vincentius-Kliniken, Medizinische Klinik 2
🇩🇪Karlsruhe, Germany
Klinikum Kassel
🇩🇪Kassel, Germany
Kliniken der Stadt Köln ggmbh, Krankenhaus Koln-Merheim/Lungenklinik
🇩🇪Köln, Germany
Universitatsklinikum Schleswig-Holstein
🇩🇪Lubeck, Germany
Johannes Wesling Klinikum Minden
🇩🇪Minden, Germany
Munchen Klinik Bogenhausen, Klinik fur Pneumologie und Pneumologische Onkologie
🇩🇪Munchen, Germany
Sana Klinikum Offenbach GmbH, Medizinische Klinik IV, Hämatologie und Internistische Onkologie
🇩🇪Offenbach, Germany
Queen Elizabeth Hospital
🇭🇰Hong Kong, Hong Kong
Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong
Prince of Wales Hospital
🇭🇰New Territories, Hong Kong
Soroka University Medical Center, Itzchak Rager Blvd.
🇮🇱Beer Seva, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Oncology Institute, Galilee Medical Center, Route 89 Nahariya-Cabri
🇮🇱Nahariya, Israel
Rabin Medical Center
🇮🇱Petah Tiqva, Israel
Kaplan Medical Center
🇮🇱Rehovot, Israel
Tel-Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Azienda Ospedaliera San Giuseppe Moscati
🇮🇹Avellino, Italy
IRCCS Fondazoine del Piemonte per l'Oncologia
🇮🇹Candiolo, Italy
Azienda Socio Sanitaria Territoriale di Cremona
🇮🇹Cremona, Italy
Ospedale Policlinico San Martino
🇮🇹Genova, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
Azienda Ospedaliero Universitaria di Modena
🇮🇹Modena, Italy
AORN Cardarelli
🇮🇹Naples, Italy
Azienda Ospedaliera dei Colli
🇮🇹Napoli, Italy
IRCCS Policlinico S. Matteo, Dipartimento Oncologia Ematologia-Oncologia Medica
🇮🇹Pavia, Italy
Azienda Sanitaria Territoriale Pesaro e Urbino (AST)
🇮🇹Pesaro, Italy
Ospedale Guglielmo da Saliceto AUSL di Piacenza
🇮🇹Piacenza, Italy
Centro di Riferimento Oncologico
🇮🇹Pordenone, Italy
Regina Elena Institute for Cancer Research
🇮🇹Rome, Italy
ASST Bergamo Ovest- ospedale di Treviglio
🇮🇹Treviglio, Italy
National Cancer Center Hospital East
🇯🇵Chiba, Japan
National Hospital Organization Shikoku Cancer Center
🇯🇵Ehime, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Kurume University Hospital
🇯🇵Fukuoka, Japan
National Hospital Organization Himeji Medical Center
🇯🇵Hyogo, Japan
Hyogo Cancer Center
🇯🇵Hyogo, Japan
Kanazawa University Hospital
🇯🇵Ishikawa, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Sendai Kousei Hospital
🇯🇵Miyagi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Osaka Metropolitan University Hospital
🇯🇵Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
🇯🇵Osaka, Japan
Kindai University Hospital
🇯🇵Osaka, Japan
National Hospital Organization Kinki Chuo Chest Medical Center
🇯🇵Osaka, Japan
Saitama Medical University
🇯🇵Saitama, Japan
SMG - SNU Boramae Medical Center
🇰🇷Dongjak-Gu, Korea, Republic of
Samsung Medical Center
🇰🇷Gangnam-Gu, Korea, Republic of
National Cancer Center
🇰🇷Goyang, Korea, Republic of
Chungbuk National University Hospital
🇰🇷Heungdeok-Gu, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Inchon, Korea, Republic of
Kosin University Gospel Hospital
🇰🇷Seo-gu, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon-si, Korea, Republic of
The Catholic University of Korea, Saint Vincent's Hospital
🇰🇷Suwon, Korea, Republic of
Health Pharma Professional Research S.A. de C.V.
🇲🇽Mexico, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
🇲🇽Mitras Centro, Mexico
Oaxaca Site Management Organization
🇲🇽Oaxaca, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca, Mexico
Clinical Medical Research SC.
🇲🇽Orizaba Centro, Mexico
Clinica Integral Internacional de Oncologia S de RL de CV
🇲🇽Puebla, Mexico
FAICIC Clínical Research
🇲🇽Veracruz, Mexico
Amphia Ziekenhuis
🇳🇱Breda, Netherlands
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Ziekenhuis St Jansdal
🇳🇱Harderwijk, Netherlands
TweeSteden Ziekenhuis
🇳🇱Tilburg, Netherlands
Hospital Prof. Doutor Fernando Fonseca
🇵🇹Amadora, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil
🇵🇹Lisboa, Portugal
Fundacao Champalimaud
🇵🇹Lisboa, Portugal
Centro Hospitalar Universitário Lisboa Norte - Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Hospital Beatriz Angelo. Hospital de Loures.
🇵🇹Lisbon, Portugal
Centro Hospitalar Universitario Sao Joao, EPE
🇵🇹Porto, Portugal
Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano SA
🇵🇹Senhora da Hora, Portugal
Raffles Hospital
🇸🇬Singapore, Singapore
Tang Tock Seng Hospital
🇸🇬Singapore, Singapore
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital de la Santa Creu i de Sant Pau
🇪🇸Barcelona, Spain
Hospital Universitari Dexeus (USP Institut Universitari Dexeus/Hospital Universitari Quiron Dexeus)
🇪🇸Barcelona, Spain
Hospital Universitari Vall D'Hebron
🇪🇸Barcelona, Spain
Hospital Parc Tauli
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Hospital Doctor Josep Trueta
🇪🇸Girona, Spain
Hospital Universitario de Jaen
🇪🇸Jaen, Spain
Hospital Universitario de Canarias
🇪🇸Las Palmas de G.C., Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Clinica Universidad de Navarra
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario Puerta de Hierro de Majadahonda
🇪🇸Majadahonda, Spain
Hospital Sant Joan de Reus
🇪🇸Reus, Spain
Hospital Regional Universitario de Malaga
🇪🇸Rincon de la Victoria, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Seville, Spain
Instituto Valenciano De Oncologia (IVO)
🇪🇸Valencia, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Hospital Vithas Valencia 9 de Octubre
🇪🇸Valencia, Spain
Changhua Christian Hospital
🇨🇳Changhua City, Taiwan
E-DA Hospital
🇨🇳Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Chang Gung Memorial Hospital Kaohsiung
🇨🇳Kaohsiung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Chi Mei Hospital, Liouying
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital Linkou Branch of the Chang Gung Medical Foundation
🇨🇳Taoyuan City, Taiwan
Ankara Bilkent Sehir Hastanesi
🇹🇷Ankara, Turkey
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
🇹🇷Ankara, Turkey
Trakya University Faculty of Medicine
🇹🇷Edirne, Turkey
Istanbul University Cerrahpasa Medical Faculty Hospital
🇹🇷Fatih, Turkey
Goztepe Prof. Dr. Suleyman Yalcın Sehir Hastanesi
🇹🇷Istanbul, Turkey
Medipol Mega University Hospital
🇹🇷Istanbul, Turkey
Acibadem Mehmet Ali Aydinlar Universitesi Atakent Hastanesi
🇹🇷Kaakaekmece, Turkey
Turgut Ozal Medical Faculty
🇹🇷Malatya, Turkey
Colchester General Hospital
🇬🇧Colchester, United Kingdom
St Bartholomew's Hospital, Barts Health NHS Trust
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust, Department of Medical Oncology
🇬🇧Manchester, United Kingdom
University Hospital Southampton Nhs Foundation Trust
🇬🇧Southampton, United Kingdom